Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes

View More View Less
  • 1 Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

✓ Human glioblastoma cells secrete factors, such as prostaglandin E (PGE) and transforming growth factor beta type 2, which are capable of suppressing several immune functions. The present study investigated the effect of PGE2 and agents known to increase intracellular cyclic adenosine monophosphate (cAMP) levels on 1) the induction of lymphokine-activated killer (LAK) cell activity from the peripheral blood lymphocytes (PBL) of both normal and glioma patients and on 2) the cytolytic activities of tumor-infiltrating lymphocytes (TIL's) isolated from malignant gliomas after expansion in vitro with interleukin-2 (IL-2). Cytolytic activity was measured against autologous and allogeneic tumor cells and the natural killer-resistant Daudi cell line. The results demonstrate that PGE2 and agents known to increase intracellular cAMP levels can significantly suppress the IL-2-dependent generation of cytolytic activity from the PBL of normal and glioma patients and from glioblastoma-derived TIL's. The inhibitory effects of these agents could not be reduced by higher concentrations of IL-2 or by cyclic guanosine monophosphate.

Although the suppressive effect of PGE2 was most significant during the early stages of LAK cell generation, an inhibitory effect was still evident when PGE2 was added directly to the cytotoxicity assay. Secretion of PGE2 by glioblastoma cells in vivo may regulate both the generation of an immune response and the effectiveness of adoptively transferred immune cells.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address reprint requests to: Maria C. Kuppner, Ph.D., Laboratoire de Neurochirurgie, CHUV, CH-1011, Lausanne, Switzerland.
  • 1.

    Bosnes V, & Hirschberg H: Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects. J Neurosurg 69:234238, 1988 Bosnes V, Hirschberg H: Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects. J Neurosurg 69:234–238, 1988

    • Search Google Scholar
    • Export Citation
  • 2.

    Castelli MG, , Chiabrando C, & Fanelli R, et al. : Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:15051508, 1989 Castelli MG, Chiabrando C, Fanelli R, et al: Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49:1505–1508, 1989

    • Search Google Scholar
    • Export Citation
  • 3.

    Chouaib S, , Robb RJ, & Welte K, et al. : Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest 80:333340, 1987 Chouaib S, Robb RJ, Welte K, et al: Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest 80:333–340, 1987

    • Search Google Scholar
    • Export Citation
  • 4.

    Chouaib S, , Welte K, & Mertelsmann R, et al. : Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down regulation of the transferrin receptor expression. J Immunol 135:11721179, 1985 Chouaib S, Welte K, Mertelsmann R, et al: Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down regulation of the transferrin receptor expression. J Immunol 135:1172–1179, 1985

    • Search Google Scholar
    • Export Citation
  • 5.

    de Martin R, , Haendler B, & Hofer-Warbinek R, et al. : Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 6:36733677, 1987 de Martin R, Haendler B, Hofer-Warbinek R, et al: Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 6:3673–3677, 1987

    • Search Google Scholar
    • Export Citation
  • 6.

    Elliot LH, , Brooks WH, & Roszman TL: Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67:231236, 1987 Elliot LH, Brooks WH, Roszman TL: Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. J Neurosurg 67:231–236, 1987

    • Search Google Scholar
    • Export Citation
  • 7.

    Elliot LH, , Brooks WH, & Roszman TL: Cytokinetic basis for the activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:12081215, 1984 Elliot LH, Brooks WH, Roszman TL: Cytokinetic basis for the activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132:1208–1215, 1984

    • Search Google Scholar
    • Export Citation
  • 8.

    Fontana A, , Hengartner H, & de Tribolet N, et al. : Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:18371844, 1984 Fontana A, Hengartner H, de Tribolet N, et al: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:1837–1844, 1984

    • Search Google Scholar
    • Export Citation
  • 9.

    Fontana A, , Kristensen F, & Dubs R, et al. : Production of prostaglandin E and an interleukin 1-like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:24132419, 1982 Fontana A, Kristensen F, Dubs R, et al: Production of prostaglandin E and an interleukin 1-like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413–2419, 1982

    • Search Google Scholar
    • Export Citation
  • 10.

    Goodwin JS, & Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 3:295315, 1983 Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 3:295–315, 1983

    • Search Google Scholar
    • Export Citation
  • 11.

    Grimm EA, , Robb RJ, & Roth JA, et al. : Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158:13561361, 1983 Grimm EA, Robb RJ, Roth JA, et al: Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158:1356–1361, 1983

    • Search Google Scholar
    • Export Citation
  • 12.

    Hadden JW, & Coffey RG: Cyclic nucleotides in mitogen-induced lymphocyte proliferation. Immunol Today 3:299305, 1988 Hadden JW, Coffey RG: Cyclic nucleotides in mitogen-induced lymphocyte proliferation. Immunol Today 3:299–305, 1988

    • Search Google Scholar
    • Export Citation
  • 13.

    Jacobs SK, , Wilson DJ, & Kornblith PL, et al. : In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64:114117, 1986 Jacobs SK, Wilson DJ, Kornblith PL, et al: In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64:114–117, 1986

    • Search Google Scholar
    • Export Citation
  • 14.

    Katz P, , Zaytoun AM, & Fauci AS: Mechanisms of human cell-mediated cytotoxicity. 1. Modulation of natural killer cell activity by cyclic nucleotides. J Immunol 129:287296, 1982 Katz P, Zaytoun AM, Fauci AS: Mechanisms of human cell-mediated cytotoxicity. 1. Modulation of natural killer cell activity by cyclic nucleotides. J Immunol 129:287–296, 1982

    • Search Google Scholar
    • Export Citation
  • 15.

    Kuppner MC, , Hamou MF, & Bodmer S, et al. : The glioblastoma derived T cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine activated killer (LAK) cells. Int J Cancer 42:562567, 1988 Kuppner MC, Hamou MF, Bodmer S, et al: The glioblastoma derived T cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine activated killer (LAK) cells. Int J Cancer 42:562–567, 1988

    • Search Google Scholar
    • Export Citation
  • 16.

    Kuppner MC, , Hamou MF, & de Tribolet N: Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 48:69266932, 1988 Kuppner MC, Hamou MF, de Tribolet N: Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 48:6926–6932, 1988

    • Search Google Scholar
    • Export Citation
  • 17.

    Kuppner MC, , Hamou MF, & Sawamura Y, et al. : Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71:211217, 1989 Kuppner MC, Hamou MF, Sawamura Y, et al: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71:211–217, 1989

    • Search Google Scholar
    • Export Citation
  • 18.

    McCrady CW, , Li F, & Grant J, et al. : Alteration of human lymphokine-activated killer cell activity by manipulation of the protein kinase C and cytosolic Ca2+. Cancer Res 48:635640, 1988 McCrady CW, Li F, Grant J, et al: Alteration of human lymphokine-activated killer cell activity by manipulation of the protein kinase C and cytosolic Ca2+. Cancer Res 48:635–640, 1988

    • Search Google Scholar
    • Export Citation
  • 19.

    Miescher S, , Whiteside TL, & Carrel S, et al. : Functional properties of tumor-infiltrating lymphocytes and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:18991907, 1986 Miescher S, Whiteside TL, Carrel S, et al: Functional properties of tumor-infiltrating lymphocytes and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899–1907, 1986

    • Search Google Scholar
    • Export Citation
  • 20.

    Miescher S, , Whiteside TL, & de Tribolet N, et al. : In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438448, 1988 Miescher S, Whiteside TL, de Tribolet N, et al: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438–448, 1988

    • Search Google Scholar
    • Export Citation
  • 21.

    Nishimura T, , Burakoff SJ, & Herrman SH: Protein kinase C required for cytotoxic T cell triggering. J Immunol 139:28882891, 1987 Nishimura T, Burakoff SJ, Herrman SH: Protein kinase C required for cytotoxic T cell triggering. J Immunol 139:2888–2891, 1987

    • Search Google Scholar
    • Export Citation
  • 22.

    Owen-Schoub LB, , Loudon WG, & Yagita M, et al. : Functional differentiation of human lymphokine activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cell Immunol 111:235246, 1988 Owen-Schoub LB, Loudon WG, Yagita M, et al: Functional differentiation of human lymphokine activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cell Immunol 111:235–246, 1988

    • Search Google Scholar
    • Export Citation
  • 23.

    Plaut M: Lymphocyte hormone receptors. Annu Rev Immunol 5:621669, 1987 Plaut M: Lymphocyte hormone receptors. Annu Rev Immunol 5:621–669, 1987

    • Search Google Scholar
    • Export Citation
  • 24.

    Rincón M, , Tugores A, & López-Rivas A, et al. : Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 18:17911796, 1988 Rincón M, Tugores A, López-Rivas A, et al: Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol 18:1791–1796, 1988

    • Search Google Scholar
    • Export Citation
  • 25.

    Rivkin I, , Rosenblatt J, & Becker EL: The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal macrophages. The inhibition of neutrophil movement and the elevation of cAMP levels by catecholamines, prostaglandins, theophylline and cholera toxin. J Immunol 115:11261134, 1975 Rivkin I, Rosenblatt J, Becker EL: The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal macrophages. The inhibition of neutrophil movement and the elevation of cAMP levels by catecholamines, prostaglandins, theophylline and cholera toxin. J Immunol 115:1126–1134, 1975

    • Search Google Scholar
    • Export Citation
  • 26.

    Sawamura Y, , Hosokawa M, & Kuppner MC, et al. : Antitumor activity and surface phenotypes of glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49:18431849, 1989 Sawamura Y, Hosokawa M, Kuppner MC, et al: Antitumor activity and surface phenotypes of glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49:1843–1849, 1989

    • Search Google Scholar
    • Export Citation
  • 27.

    Siepl C, , Bodmer S, & Frei K, et al. : The glioblastoma-derived T cell suppressor factor/transforming growth factor β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593600, 1988 Siepl C, Bodmer S, Frei K, et al: The glioblastoma-derived T cell suppressor factor/transforming growth factor β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593–600, 1988

    • Search Google Scholar
    • Export Citation
  • 28.

    Slauson DO, , Walker C, & Kristensen F, et al. : Mechanisms of serotonin-induced lymphocyte proliferation inhibition. Cell Immunol 84:240252, 1984 Slauson DO, Walker C, Kristensen F, et al: Mechanisms of serotonin-induced lymphocyte proliferation inhibition. Cell Immunol 84:240–252, 1984

    • Search Google Scholar
    • Export Citation
  • 29.

    Smith JW, , Steiner AL, & Parker CW: Human lymphocyte metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 50:442449, 1971 Smith JW, Steiner AL, Parker CW: Human lymphocyte metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 50:442–449, 1971

    • Search Google Scholar
    • Export Citation
  • 30.

    Wrann M, , Bodmer S, & de Martin R, et al. : T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 6:16331636, 1987 Wrann M, Bodmer S, de Martin R, et al: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 6:1633–1636, 1987

    • Search Google Scholar
    • Export Citation
  • 31.

    Zuber P, , Kuppner MC, & de Tribolet N: Transforming growth factor β2 downregulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18:16231626, 1988 Zuber P, Kuppner MC, de Tribolet N: Transforming growth factor β2 downregulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18:1623–1626, 1988

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 383 75 4
Full Text Views 157 6 0
PDF Downloads 91 7 0
EPUB Downloads 0 0 0